WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.
Boulder and CBD: The Entourage Effect Explained
If you use CBD products, understanding the entourage effect helps explain why full-spectrum formulations may offer greater therapeutic benefit than isolated CBD alone. An overview of the entourage effect explains how CBD works synergistically with other cannabinoids, terpenes, and flavonoids found naturally in full-spectrum hemp products to produce enhanced therapeutic outcomes compared to isolated CBD alone. The concept is supported by preclinical and emerging clinical data showing that combinations of non-psychotropic cannabinoids such as CBG, CBN, and CBDV amplify anti-inflammatory, anxiolytic, and analgesic effects.
United States Drug Enforcement Administration Cannabis-Related Documents
Understanding how the DEA classifies cannabis compounds is essential for patients and providers navigating the increasingly complex legal landscape between hemp, CBD, and controlled substances. The DEA has published an updated collection of cannabis-related regulatory and scheduling documents, providing a consolidated federal reference for the current legal classification and enforcement framework surrounding marijuana and hemp-derived cannabinoids. These documents detail the Controlled Substances Act scheduling criteria, enforcement guidance, and regulatory interpretations that shape how cannabis products are classified at the federal level.
Satiety Bypass: How Cannabis Overrides the Brain’s ‘I’m Full’ Signal
A massive study tracking over 460,000 teens found that cannabis use during adolescence doubled the risk of psychotic and bipolar disorders, underscoring why age restrictions and youth prevention are critical. Neuroscience News deep-dive into the WSU/Calgary PNAS study on cannabis-induced appetite. THC activates CB1 receptors in the hypothalamus to override natural satiety signals, creating a feeling of starvation even in recently fed subjects.
Cannabis-Related ‘Munchies’ Are Real, and Could Help People with AIDS, Cancer
If you struggle with insomnia, this data shows medical cannabis provided sustained sleep improvement for 18 months, with nearly 40% of patients reducing or quitting their prescription sleep medications. A collaborative study by WSU and University of Calgary, published in PNAS, confirms ‘the munchies’ are a real cognitive response that occurs regardless of sex, age, weight, or recent food consumption. In a randomized clinical trial of 82 volunteers who vaped 20 or 40mg of cannabis or placebo, intoxicated participants ate significantly more food within the first 30 minutes.
Texas Voters Weigh In on Marijuana Legalization in Primary Election
Massachusetts crossing $9 billion in legal cannabis sales proves that regulated markets work—generating tax revenue, creating jobs, and giving consumers access to safe, tested products. Marijuana legalization is on the primary election ballot in Texas, marking a significant moment for cannabis reform in one of the nation’s most conservative states and a major hemp-producing state. The ballot measure tests voter appetite for legalization in a state that has maintained strict cannabis laws while building a massive hemp industry.
CBD and Liver Enzymes: What the New JAMA Study Actually Shows
A new peer-reviewed study sent ripples through the CBD world—but what does it actually say about liver health? Spoiler: it’s not as simple as “CBD is dangerous.” When you zoom in on the details, the real story is about dose, data, and the difference between panic and perspective.